Results pending
Walking (potassium-channel blockade): improve symptoms or function in relapsing MS
relapsing MS · Walking (potassium-channel blockade)
Trials have finished, but some results have not been read yet. There is no verdict until they are, because one unread trial can change the answer.
- Trials
- 2
- Running now
- 0
- Controlled phase 2/3 trials
- 1
- People in controlled trials
- 120
No controlled trial has reported a result yet.
Other linked trials: 2
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
Other linked trials: 2
These linked trials do not set the status.
- Fatigue in Multiple Sclerosis: Evaluated With 3 MRI and Transcranial Magnetic StimulationNo result found
Phase 2 · 2006 · Placebo-controlled
- Dalfampridine in Egyptian Patients With Multiple SclerosisResult in a paper, not read yet
Phase not applicable · 2021 · Placebo-controlled
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-27First listed as Results pending
Related hypotheses
- Walking (potassium-channel blockade): improve symptoms or function in NMOSD
- Walking (potassium-channel blockade): improve symptoms or function in optic neuritis
- Walking (potassium-channel blockade): improve symptoms or function in primary progressive MS
- Walking (potassium-channel blockade): improve symptoms or function in relapsing and progressive MS
- Walking (potassium-channel blockade): improve symptoms or function in secondary progressive MS
- Walking (potassium-channel blockade): improve symptoms or function in MS (type not specified)
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error